Comment[ArrayExpressAccession]	E-MTAB-3472
MAGE-TAB Version	1.1				
Investigation Title	Transcriptomics analysis of CNOT6L KD LHCN cells compared to control				
Comment[Submitted Name]	Transcriptomics analysis of CNOT6L KD LHCN cells compared to control
Experiment Description	we transiently transfected LHCN cells (human skeletal myoblasts) with a CNOT6L-targeting siRNA or with an irrelevant siRNA as control. Cells were then placed under differentiation conditions for 2 days and total mRNA used for microarray analysis				
Experimental Factor Name	RNA interference				
Experimental Factor Type	RNA interference				
Experimental Factor Term Source REF					
Experimental Factor Term Accession Number					
Person Last Name	Cindy				
Person First Name	Degerny				
Person Mid Initials					
Person Email	cindy.degerny@u-psud.fr				
Person Phone					
Person Fax					
Person Address					
Person Affiliation					
Person Roles	submitter				
Date of Experiment	2013-02-02				
Public Release Date	2015-12-25				
Protocol Name	P-MTAB-44199	P-MTAB-44200	P-MTAB-44201	P-MTAB-44202	P-MTAB-44203
Protocol Type	growth protocol	treatment protocol	nucleic acid extraction protocol	nucleic acid labeling protocol	nucleic acid hybridization to array protocol
Protocol Term Source REF	EFO	EFO	EFO	EFO	EFO
Protocol Term Accession Number	EFO_0003789	EFO_0003969	EFO_0002944	EFO_0003813	EFO_0003815
Protocol Description	LHCN-M2 immortalized human myoblasts [15] were grown in 80% Dubelco’s Modified Eagle’s Medium (DMEM, Invitrogen 61965), 20% 199 medium (v/v, Invitrogen 41150) supplemented with 20% Fetal Bovine Serum (v/v, PAA A 04306-0360), penicillin/streptomycin (100 units/mL of penicillin and 100 µg/mL of streptomycin, Invitrogen) and plasmocin (2.5 μg/mL, Invivogen). For differentiation assays, cells were seeded into collagen-coated plates (rat tail collagen, 100µg/mL in ddH2O + 0.2% acetic acid [v/v], Sigma C7661) at 2.104 cells/well (black-walled clear bottom 96-well plate, Costar 3904), or 5x105 cells/well (6-well plate, TPP). Differentiation was induced by media replacement with DMEM supplemented with antibiotics, insulin (10µg/mL, Life Technologies) and transferrin (100µg/mL, Life Technologies). 	siRNAs were reverse transfected at 10nM final in 96- or 6-well format using Lipofectamine RNAiMAX (Invitrogen) according to manufacturer’s conditions. 	RNA were extracted according to Trizol protocol	Labeling was done according to GeneChip® WT Terminal Labeling and Hybridization User Manual for use with the Ambion® WT Expression Kit	Hybridization was done according to GeneChip® WT Terminal Labeling and Hybridization User Manual for use with the Ambion® WT Expression Kit
Protocol Hardware					
Protocol Software					
Term Source Name	ArrayExpress	EFO
Term Source File	http://www.ebi.ac.uk/arrayexpress/	http://www.ebi.ac.uk/efo/			
Term Source Version					
Comment[AEExperimentType]	transcription profiling by array				
SDRF File	E-MTAB-3472.sdrf.txt